IRIDEX Corporation (NASDAQ: IRIX) is a medical technology company dedicated to the development, manufacturing and commercial distribution of innovative laser and light-based products for the treatment of glaucoma and other common retinal conditions. Headquartered in Mountain View, California, the company’s product offerings encompass both surgical and therapeutic devices that are used by ophthalmologists and retinal specialists around the world. IRIDEX’s flagship technologies include pattern scan lasers for efficient retinal photocoagulation and microPulse lasers designed for minimally invasive glaucoma therapy, reflecting its commitment to precision treatment and patient safety.
Since its founding in 1989, IRIDEX has expanded its global footprint through a combination of direct sales in the United States and strategic partnerships across Europe, Asia-Pacific, Latin America and the Middle East. The company’s robust distribution network ensures broad access to its laser platforms, handpieces, probes and consumables, while its field-based clinical specialists offer in‐depth training and support to eye care professionals. IRIDEX also invests in ongoing clinical research and publication initiatives to validate clinical outcomes, further reinforcing its reputation as a trusted partner for advancing ophthalmic care.
The IRIDEX product portfolio serves a diverse range of ocular indications, from the management of diabetic retinopathy and macular edema to the treatment of open-angle and neovascular glaucoma. Its patented microPulse® technology delivers energy in short pulses, reducing thermal damage to surrounding tissue and improving patient comfort. Complementing its laser platforms are diagnostic accessories and software that enable practitioners to accurately target treatment zones and monitor laser performance, underscoring the company’s end-to-end approach to clinical workflow.
Guided by an experienced executive leadership team, IRIDEX continues to innovate in response to evolving clinical needs and regulatory standards. The company maintains a dedicated research and development hub in Mountain View, while its manufacturing facility in California adheres to stringent quality management systems. Through a strategic focus on product enhancement, clinical collaboration and geographic expansion, IRIDEX aims to strengthen its position as a leader in ophthalmic laser therapies and to support clinicians in improving outcomes for patients worldwide.
AI Generated. May Contain Errors.